Kidney Cancer Drugs Market Report 2025

The kidney cancer drugs market size has grown strongly in recent years. It will grow from $8.2 billion in 2024 to $8.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increased healthcare expenditure, rapid growth in elderly population, increase in pharmaceutical R&D expenditure, and advances in cancer drug discovery.

The kidney cancer drugs market size is expected to see steady growth in the next few years. It will grow to $10.48 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increasing geriatric population, rise in healthcare expenditure, rise in acquisitions and partnerships for drug development, and high potential of emerging economies. Major trends in the forecast period include adopting 3D technology in manufacturing drugs and create models, investing in biomarkers, launching or adopting new treatment developments, improve treatment by offering personalized medicine, invest in ai solutions, and collaborating and partnering with other companies or government bodies to accelerate the development of new drugs.

The surge in the incidence of renal cancer stands out as a significant driver of the kidney cancer drugs market. Lifestyle changes, tobacco consumption, and an unhealthy diet contribute to the proliferation of renal cancer cells. For example, the American Cancer Society reported in January 2022 that approximately 79,000 new cases of kidney cancer (50,290 in men and 28,710 in women) are expected to be diagnosed, resulting in 13,920 fatalities (8,960 in men and 4,960 in women). The majority of diagnoses occur between the ages of 65 and 74, with an average age of diagnosis being 64. Kidney cancer is relatively rare in individuals under the age of 45, emphasizing the driving force behind the growth of the kidney cancer drugs market.

Government initiatives and funding addressing kidney disorders are anticipated to propel the kidney cancer drugs market's growth. Government initiatives and funding provide financial support to entities and projects contributing to public services and the economy. These initiatives enhance disease surveillance, raise awareness, and promote research in kidney disorders. For instance, in July 2022, the United States House Committee on Appropriations initiated investment programs to boost kidney health. This includes $8.5 million in funding for the Centers for Disease Control and Prevention's chronic kidney disease program, aimed at promoting awareness, diagnosis, and treatment. Additionally, a living donation investment of $1 million was allocated to the national living donor assistance center, bringing the total to $8 million for innovation and research. Consequently, government initiatives and funding for kidney disorders play a pivotal role in driving the kidney cancer drugs market's growth.

Leading companies in the kidney cancer drugs market are prioritizing technologies like biosimilar development to expand treatment options, increase patient access to affordable therapies, and drive innovation in cancer care. Biosimilar development involves creating biological drugs that closely resemble an already approved reference product, offering comparable efficacy, safety, and quality. For example, in November 2022, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, launched RELEUKO (filgrastim-ayow), a biosimilar to Neupogen (filgrastim), developed to treat neutropenia, particularly in patients undergoing chemotherapy.

Leading companies in the kidney cancer drugs market are also focused on technologies like shelf stability to extend product longevity, improve storage convenience, and provide reliable access to essential treatments for patients and healthcare providers. Shelf stability technology includes formulations and packaging strategies that increase the shelf life of pharmaceuticals without the need for refrigeration or special handling. This approach ensures drugs remain effective and safe over a longer period, enhancing storage and distribution convenience. For instance, in April 2024, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, introduced PEMRYDI RTU, the first ready-to-use version of pemetrexed for injection that requires no reconstitution, dilution, or refrigeration, streamlining preparation for healthcare providers.

In October 2022, LG Chem, Ltd. acquired AVEO Oncology for $566 million. This acquisition positions LG Chem's Life Sciences Division in the U.S., diversifies its pipeline with various oncology treatments, and accelerates LG Chem's growth efforts in the oncology sector. The collaboration aims to establish a global oncology organization with a robust portfolio, spanning from discovery to clinical development, biologics manufacturing, and U.S. commercialization, ultimately broadening access to treatment options. AVEO Oncology is a U.S.-based biopharmaceutical company committed to delivering cancer patients drugs that enhance their quality of life.

Major companies operating in the kidney cancer drugs market include Pfizer Inc., Novartis AG, ExelixisInc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Amgen Inc., Biocon Ltd, Rani Therapeutics, Eli Lilly and Company, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc, AVEO Oncology, Teva Pharmaceutical Industries Ltd., Kitov Pharma Limited, CureTech Ltd., Neopharma.

North America was the largest region in the kidney cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Kidney cancer drugs are designed to treat kidney cancer through systemic therapy, reaching cancer cells throughout the body. Various medications may be employed, depending on the type of kidney cancer. These drugs work by targeting key proteins, such as tyrosine kinases, crucial for the growth and survival of cancer cells, or by inhibiting angiogenesis, the formation of new blood vessels that nourish tumors.

The main types of kidney cancer include renal cell carcinoma (RCC), urothelial carcinoma, and others (renal sarcoma, renal lymphoma). Renal cell carcinoma is a condition where malignant cells form in the kidney's tubules. Different products involved in treating kidney cancer include Nexavar (sorafenib), Sutent (sunitinib), Afinitor (everolimus), Voting (pazopanib), Avastin (bevacizumab), Inlyta (axitinib), Torisel (temsirolimus), Proleukin (aldesleukin), and others. These drugs are used by hospitals, clinics, research centers, and similar healthcare facilities.

The kidney cancer drugs market research report is one of a series of new reports that provides kidney cancer drugs market statistics, including kidney cancer drugs industry global market size, regional shares, competitors with a kidney cancer drugs market share, detailed kidney cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the kidney cancer drugs industry. This kidney cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney cancer drugs market consists of sales of axitinib (Inlyta), cabozantinib (cabometyx), and pazopanib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.